Carlos Buesa, PhD is the founder of Oryzon Genomics and has served as Chief Executive Officer since then. Oryzon is a biopharmaceutical company that is considered a European leader in epigenetics. Oryzon is currently conducting Phase III clinical trial evaluating their epigenetic compound vafidemstat in the treatment of Borderline Personality Disorder.

Dr. Buesa holds a PhD in Biology from the University of Barcelona, was a postdoctoral researcher with a European Union grant and Senior Researcher at the Flemish Institute of Biotechnology (VIB). In recent years he has been a director of various biotechnology companies. He was the first President of the Catalan Association of Biocompanies (CataloniaBio) and has been a member and Vice-President representing Oryzon on the Board of Directors of the Spanish Association of Biocompanies.